TelehealthTELETNCT05311241
Teleconsultation in Ambulatory Care in France
An observational study of Telehealth and Telemedicine, run by Les Entreprises de Télémédecine at 1 site in France.
Trial summary
Teleconsultation is a telemedicine medical act carried out remotely via information and communication technologies. This medical procedure has been legal in France since 2010 and reimbursed by the National Health Insurance under certain conditions since 2018. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Telehealth, Telemedicine, Teleconsultation
- How many people
- 84,000 participants
- Where
- 1 siteFrance
- Study dates
- 1 Feb 2022to 21 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients registered with a teleconsultation company member of the LET participating to the study with at least one teleconsultation during the study period.
Who may be able to join
- Patient who used the teleconsultation access service with one of the telemedicine companies member of the LET participating in the study
- Patient residing in France according to the written information (address and or postal code) given at registration to the telemedicine company
- Teleconsultation service used between August 1, 2021 and November 30, 2021
- Teleconsultation service used in the context of outpatient care (hospitals excluded)
- Teleconsultation service used for a teleconsultation with a doctor registered with the Medical Doctors Council in France
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Observational Study of the Use of the Service Giving Access to Teleconsultation in France by Telemedicine Companies
Teleconsultation is a telemedicine medical act carried out remotely via information and communication technologies. This medical procedure has been legal in France since 2010 and reimbursed by the National Health Insurance under certain conditions since 2018. In 2020, following the COVID-19 epidemic, the lockdowns and the extension of the scope of financial coverage, 17 million teleconsultations have been reimbursed.
To date, few scientific studies have been published in France to precisely describe the use of the service giving access to outpatient teleconsultation, in particular since the major increase in activity linked to the COVID-19 epidemic.
The objective is to describe the use of the service giving access to outpatient teleconsultation carried out in France by teleconsultation companies and compare the use of the teleconsultation service according to the medical density of the territory.
- Conditions
- Telehealth, Telemedicine, Teleconsultation
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of patients without a treating doctor
Measured: Through the study completion at the time of the teleconsultation, average 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Apr 2022
- Study start1 Feb 2022
- Primary completion21 Mar 2022
- Study completion21 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for TelehealthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 84,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Les Entreprises de Télémédecine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Julie Salomon, MD, Principal investigator, Qare
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05311241
- Sponsor's protocol ID
- 001
- Acronym
- TELET
- Status last verified
- Apr 2022
- First submitted
- 25 Mar 2022
- Last updated
- 5 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ohannessian R, Yaghobian S, Simon R, Poinsot-Chaize G, Hiridjee S, Gleize JC, Pierme JP, Amar N, Merlaud C, Maudoux C, Zerah B, Lescure F, Salomon J. Evaluating the Impact of Teleconsultations on Access to Ambulatory Primary Care in Medically Underserved Areas: A National Observational Cross-Sectional Multicenter Study. Telemed J E Health. 2024 Feb;30(2):570-578. doi: 10.1089/tmj.2023.0274. Epub 2023 Aug 29.
PubMed 37643308
Study at a glance
From the registry record, last updated by the sponsor on 5 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study of the Use of the Service Giving Access to Teleconsultation in France by Telemedicine Companies
- ClinicalTrials.gov ID
- NCT05311241
- Acronym / sponsor ID
- TELET / 001
- Conditions
- Telehealth, Telemedicine, Teleconsultation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 84,000 participants (actual)
- Lead sponsor
- Les Entreprises de TélémédecineUniversity, hospital or other
- Study start
- 1 Feb 2022 (actual)
- Primary completion
- 21 Mar 2022 (actual)
- Study completion
- 21 Mar 2022 (actual)
- First posted
- 5 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Teleconsultation is a telemedicine medical act carried out remotely via information and communication technologies. This medical procedure has been legal in France since 2010 and reimbursed by the National Health Insurance under certain conditions since 2018. In 2020, following the COVID-19 epidemic, the lockdowns and the extension of the scope of financial coverage, 17 million teleconsultations have been reimbursed.
To date, few scientific studies have been published in France to precisely describe the use of the service giving access to outpatient teleconsultation, in particular since the major increase in activity linked to the COVID-19 epidemic.
The objective is to describe the use of the service giving access to outpatient teleconsultation carried out in France by teleconsultation companies and compare the use of the teleconsultation service according to the medical density of the territory.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients registered with a teleconsultation company member of the LET participating to the study with at least one teleconsultation during the study period.
Key inclusion criteria (5 listed)
- Patient who used the teleconsultation access service with one of the telemedicine companies member of the LET participating in the study
- Patient residing in France according to the written information (address and or postal code) given at registration to the telemedicine company
- Teleconsultation service used between August 1, 2021 and November 30, 2021
- Teleconsultation service used in the context of outpatient care (hospitals excluded)
- Teleconsultation service used for a teleconsultation with a doctor registered with the Medical Doctors Council in France
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Rate of patients without a treating doctor
Time frame: Through the study completion at the time of the teleconsultation, average 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Apr 2022.
- Derived from this study: PubMed 37643308Ohannessian R, Yaghobian S, Simon R, Poinsot-Chaize G, Hiridjee S, Gleize JC, Pierme JP, Amar N, Merlaud C, Maudoux C, Zerah B, Lescure F, Salomon J. Evaluating the Impact of Teleconsultations on Access to Ambulatory Primary Care in Medically Underserved Areas: A National Observational Cross-Sectional Multicenter Study. Telemed J E Health. 2024 Feb;30(2):570-578. doi: 10.1089/tmj.2023.0274. Epub 2023 Aug 29.
- Individual participant dataSharing planned: No
Related trials for Telehealth
Recruiting
Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Recruiting
Telerehabilitation Compared With Clinic-Based Physiotherapy in Children With Spastic Cerebral Palsy
Spastic Cerebral Palsy
Recruiting
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
Obesity, Smoking Cessation
Active, not recruiting
Enhancing Telemedicine for T2D
Type 2 Diabetes
Recruiting
The Impact of Telemedicine, Using the Caller's Mobile Phone Camera, on the Quality of Care Provided to Adult Patients Contacting the 15 Centre for Acute Dyspnea
Dyspnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Julie Salomon, MD principal investigator
Qare
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Telehealth and Telemedicine, run by Les Entreprises de Télémédecine at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of patients without a treating doctor (time frame: Through the study completion at the time of the teleconsultation, average 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05311241, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2022.